Alkermes plc (ALKS)
NASDAQ: ALKS · Real-Time Price · USD
55.08
+2.25 (4.26%)
At close: Jun 26, 2026, 4:00 PM EDT
54.64
-0.44 (-0.80%)
After-hours: Jun 26, 2026, 7:00 PM EDT
Alkermes Employees
Alkermes had 2,050 employees as of December 31, 2025. The number of employees increased by 250 or 13.89% compared to the previous year.
Employees
2,050
Change (1Y)
250
Growth (1Y)
13.89%
Revenue / Employee
$762,098
Profits / Employee
$74,498
Market Cap
9.18B
Employees Chart
Employees History
Related Stocks
| Company Name | Employees |
|---|---|
| Viatris | 30,000 |
| Dr. Reddy's Laboratories | 27,527 |
| Elanco Animal Health | 9,900 |
| Amneal Pharmaceuticals | 8,700 |
| Hims & Hers Health | 2,442 |
| Neurocrine Biosciences | 2,000 |
| United Therapeutics | 1,400 |
| Lantheus Holdings | 1,193 |
ALKS News
- 2 days ago - Biotech ETF Index Surges 10% After Rebalance - ETF Trends
- 3 days ago - Alkermes price target raised to $61 from $54 at Needham - TheFly
- 5 days ago - Alkermes price target raised to $50 from $42 at TD Cowen - TheFly
- 9 days ago - Alkermes data support alixorexton in narcolepsy type 2, says H.C. Wainwright - TheFly
- 9 days ago - Alkermes reports ‘positive results’ from Vibrance-2 Phase 2 study of alixorexton - TheFly
- 9 days ago - Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026 - Business Wire
- 10 days ago - Alkermes Slides: FY 2026 - Filings
- 12 days ago - Alkermes announces ODD for Alixorexton in the U.S., Europe - TheFly